On 2 Dec 2023, the latest clinical trial about TQB2450 for the treatment for patients with hepatocellular carcinoma at high risk of recurrence was presented in 2023 ESMO_ASIA.

LEO Pharma Inc. has disclosed that the FDA has recently broadened the sanctioned use of Adbry (tralokinumab-ldrm) by authorizing its application for young individuals.

Liposomal drug delivery systems are unique formulations that have gained significant attention in recent years due to their ability to enhance the pharmacokinetics and targeting of certain medications.

The development of TNF inhibitors has been a significant advancement in the treatment of autoimmune diseases.

Developing effective gene delivery systems for gene therapy is a significant challenge due to several factors.

FDA greenlights the unique combination of enfortumab vedotin (PADCEV®) and pembrolizumab (KEYTRUDA®), marking the first coalescence of an ADC and PD-1 inhibitor to combat progressive bladder carcinoma.

Federal regulations require that applicable clinical trials and NIH-funded clinical trials be registered no later than 21 days after enrollment of the first participant.

Telomerase inhibitors are drugs that target the enzyme telomerase, crucial in maintaining DNA integrity and stability.

When placing physical distances in the workplace in the event of an infectious disease, it is important to consider several factors.

Cullinan Oncology has initiated a Phase 1 study of CLN-617, an innovative biologic that combines the properties of IL-2 and IL-12 cytokines

the latest clinical results of Anlotinib Dihydrochloride were presented in 2023 ESMO_ASIA.

CSL, a major biotech player, announced that the FDA has accepted its application for the once-monthly hereditary angioedema preventative drug, garadacimab (CSL312).